AstraZeneca and Neurimmune sign deal to develop and commercialise treatment for fatal condition ATTR-CMProactive Investors • 01/07/22
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing PactBenzinga • 01/03/22
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenBusiness Wire • 12/28/21
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 12/25/21
DESTINY-Lung04 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Mutant Metastatic Non-Small Cell Lung CancerBusiness Wire • 12/23/21
AstraZeneca says independent study indicates efficacy of its COVID-19 vaccine against Omicron variantProactive Investors • 12/23/21
Dow Jones Newswires: AstraZeneca says COVID-19 booster effective against omicron in studyMarket Watch • 12/23/21
AstraZeneca's lupus treatment Saphnelo recommended for approval in the EUProactive Investors • 12/20/21
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should KnowZacks Investment Research • 12/18/21